Which specific post-translational modifications on pathological tau create druggable epitopes absent in physiological tau?

PARTIALLY ADDRESSED

The debate mentioned tau PTM targeting but did not identify which modifications are both disease-specific and accessible for therapeutic intervention. This knowledge gap limits the development of PTM-based selective targeting approaches. Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)

Priority: 0.79 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Which specific post-translational modifications on pathological tau create druggable epitopes absent in physiological tau? is a 0.79 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Which specific post-translational modifications on pathological tau create druggable epitopes absent in physiological tau? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
1
Debates
0.50
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
🎭 Which specific post-translational modifications on pathologi q=0.50 2026-04-10T05:33
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps